108 related articles for article (PubMed ID: 7894968)
21. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
22. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H
J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771
[TBL] [Abstract][Full Text] [Related]
23. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
24. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
Dickinson RP; Dack KN; Long CJ; Steele J
J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
[TBL] [Abstract][Full Text] [Related]
25. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
28. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
[TBL] [Abstract][Full Text] [Related]
29. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
30. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
Meade CJ; Muacevic G; Ward P; Soyka R
Jpn J Pharmacol; 1996 Jun; 71(2):119-27. PubMed ID: 8835638
[TBL] [Abstract][Full Text] [Related]
33. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. IV. 2-[2-(1-Imidazolyl)ethyl]-4-(3-pyridyl)-1(2H)-phthalazinones.
Yamaguchi M; Koga T; Kamei K; Akima M; Maruyama N; Kuroki T; Hamana M; Ohi N
Chem Pharm Bull (Tokyo); 1994 Sep; 42(9):1850-3. PubMed ID: 7954937
[TBL] [Abstract][Full Text] [Related]
34. Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines.
Archibald JL; Bradley G; Opalko A; Ward TJ; White JC; Ennis C; Shepperson NB
J Med Chem; 1990 Feb; 33(2):646-52. PubMed ID: 2299629
[TBL] [Abstract][Full Text] [Related]
35. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Rolin S; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Bioorg Med Chem Lett; 2001 Apr; 11(8):1019-22. PubMed ID: 11327579
[TBL] [Abstract][Full Text] [Related]
36. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
[TBL] [Abstract][Full Text] [Related]
37. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.
Bhagwat SS; Gude C; Cohen DS; Dotson R; Mathis J; Lee W; Furness P
J Med Chem; 1993 Jan; 36(2):205-10. PubMed ID: 8423593
[TBL] [Abstract][Full Text] [Related]
38. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
Dogné JM; Wouters J; Rolin S; Michaux C; Pochet L; Durant F; Delarge J; Masereel B
J Pharm Pharmacol; 2001 May; 53(5):669-80. PubMed ID: 11370706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
